[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100346375":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":33,"centralContacts":38,"locations":46,"responsibleParty":66,"collaborators":32,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":70,"sex":76,"minAge":77,"maxAge":32,"enrollmentInfo":78,"targetDuration":32,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":49,"whyStopped":32,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"Campus Bio-Medico University","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"DAPT","EXPERIMENTAL","\"Dual antiplatelet therapy\": acetylsalicylic acid 100 mg\u002Fdie + ticagrelor 90 mg bis in die",[13,14],"Drug: Ticagrelor","Drug: acetylsalicylic acid",{"label":16,"type":17,"description":18,"interventionNames":19},"SAPT","ACTIVE_COMPARATOR","\"Single antiplatelet therapy\": acetylsalicylic acid 100 mg\u002Fdie",[14],[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Ticagrelor","90 mg bis in die",[9],[27],"Brilique",{"type":22,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"acetylsalicylic acid","100 mg die",[9,16],null,[34],{"name":35,"affiliation":36,"role":37},"Massimo Chello, MD","Università Campus Bio-Medico di Roma, Rome, Italy","STUDY_CHAIR",[39,44],{"name":40,"role":41,"phone":42,"phoneExt":32,"email":43},"Antonio Nenna, MD","CONTACT","+393337014743","a.nenna@unicampus.it",{"name":35,"role":41,"phone":32,"phoneExt":32,"email":45},"m.chello@unicampus.it",[47],{"facility":48,"status":49,"city":50,"state":32,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"Università Campus Bio-Medico di Roma","RECRUITING","Rome","00128","Italy","IT",{"type":55,"coordinates":56},"Point",[57,58],12.51133,41.89193,{"lat":58,"lon":57},[61,62,63,65],{"name":40,"role":41,"phone":42,"phoneExt":32,"email":43},{"name":35,"role":41,"phone":32,"phoneExt":32,"email":45},{"name":40,"role":64,"phone":32,"phoneExt":32,"email":32},"PRINCIPAL_INVESTIGATOR",{"name":35,"role":64,"phone":32,"phoneExt":32,"email":32},{"type":64,"investigatorFullName":40,"investigatorTitle":67,"investigatorAffiliation":5,"oldNameTitle":32,"oldOrganization":32},"Cardiovascular Surgery","100346375","phase-3-sapt-versus-dapt-in-incomplete-revascularization-after-cabg-100346375",false,"NCT03789916","SAPT Versus DAPT in Incomplete Revascularization After CABG","Single Versus Dual Antiplatelet Therapy in Patients With Incomplete Revascularization After Coronary Artery Bypass Graft Surgery","SDAT-IRC","Inclusion Criteria:\n\n* patients undergoing CABG, ± cardiopulmonary bypass, ± any associated cardiac procedures (valve replacement,...)\n* incomplete myocardial revascularization, defined by anatomic or functional criteria\n* obtained informed consent\n\nExclusion Criteria:\n\n* acute coronary syndrome \\\u003C 12 months from surgery\n* dual antiplatelet therapy at hospital admission\n* planned procedure to complete myocardial revascularization (e.g. hybrid approach)\n* intolerance \u002F unable to take acetylsalicylic acid or ticagrelor\n* preoperative atrial fibrillation\n* impaired compliance\n* planned pregnancy\n* history of gastrointestinal bleeding\n* chronic kidney disease (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m2)\n* chronic liver disease\n* severe heart failure at hospital admission\n* active malignancy\n* alcohol abuse\n* any clinical condition not compatible with the treatment\n\nExit Criteria:\n\n* postoperative atrial fibrillation requiring anticoagulation\n* postoperative hemorrhagic events (stroke, GI bleeding)\n* occurrence of contraindications to acetylsalicylic acid or ticagrelor\n* surgical treatment requiring DAPT withdrawn\n* patient decision","ALL","18 Years",{"count":79,"type":80},800,"ESTIMATED","INTERVENTIONAL",[83],"PHASE3","The study aims to compare the efficacy of dual antiplatelet therapy (DAPT) over single antiplatelet therapy (SAPT) in patients with incomplete revascularization after coronary artery bypass graft surgery (CABG).\n\nBefore hospital discharge, patients will be 1:1 randomized to SAPT (acetylsalicylic acid 100 mg\u002Fdie) or DAPT (acetylsalicylic acid 100 mg\u002Fdie + ticagrelor 90 mg bis in die). DAPT will be continued for 12 months, and ticagrelor will be withdrawn thereafter. Primary endpoint is the evaluation of cardiac-related mortality at 5 years from hospital discharge.",[86],"Coronary Artery Disease",[88,89,90,91],"coronary artery bypass grafting","incomplete revascularization","coronary artery disease","dual antiplatelet therapy","2022-07-19",{"date":94,"type":95},"2022-07-21","ACTUAL",{"date":97,"type":95},"2019-01-02",{"date":99,"type":80},"2026-12-31",{"name":5,"class":6},1]